Statistics for Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
Total visits
| views | |
|---|---|
| Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer | 75 |
Total visits per month
| views | |
|---|---|
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
File Visits
| views | |
|---|---|
| 41416_2020_Article_1041.pdf | 44 |
| java.util.UUID:713e82da-e2d6-4a01-bb76-616f764f257b | 41 |
| java.util.UUID:931a6576-869e-4ef0-85a0-6013bc3be463 | 22 |
| java.util.UUID:7fbcea70-54bc-4888-921f-06794b32d270 | 6 |
Top country views
| views | |
|---|---|
| United States | 65 |
| China | 1 |
| South Korea | 1 |
| Malaysia | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 42 |
| White Plains | 9 |
| Fairfield | 5 |
| Houston | 3 |
| Ann Arbor | 1 |
| Beijing | 1 |
| Cambridge | 1 |
| Concord | 1 |
| Seoul | 1 |
| Seremban | 1 |